Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of L608 in Healthy Participants
NCT06429930Phase 1Recruiting
- Sponsor
- Pharmosa Biopharm Inc.
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of iloprost in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Pharmosa Biopharm Inc. Primary endpoints: Dose-Limiting Toxicity at 7 days and Treatment-Emergent Adverse Events and Serious Adverse Events at 2 weeks. Started Apr 2025; status: recruiting.
02
Drugs
iloprost
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06429930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429930.